

Katherine B Peters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/52880/publications.pdf>

Version: 2024-02-01

154
papers

2,494
citations

257450

24
h-index

223800

46
g-index

155
all docs

155
docs citations

155
times ranked

3382
citing authors

#	ARTICLE	IF	CITATIONS
1	Caregiver burden by treatment and clinical characteristics of patients with glioblastoma. <i>Supportive Care in Cancer</i> , 2022, 30, 1365-1375.	2.2	8
2	Pineal Parenchymal Tumors of Intermediate Differentiation Treated With Ventricular Radiation and Temozolomide. <i>Advances in Radiation Oncology</i> , 2022, 7, 100814.	1.2	5
3	Availability and Role of Clinical Pharmacists in Ambulatory Neuro-Oncology. <i>Neuro-Oncology Practice</i> , 2022, 9, 18-23.	1.6	0
4	Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial. <i>Supportive Care in Cancer</i> , 2022, 30, 3463-3471.	2.2	3
5	Rural-Urban Disparities in Cancer Outcomes: Opportunities for Future Research. <i>Journal of the National Cancer Institute</i> , 2022, 114, 940-952.	6.3	46
6	Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma. <i>Oncotarget</i> , 2022, 13, 576-582.	1.8	4
7	Cold Plasma Discharge Tube Enhances Antitumoral Efficacy of Temozolomide. <i>ACS Applied Bio Materials</i> , 2022, 5, 1610-1623.	4.6	11
8	Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplantation Candidates Age 18 to 80 Years. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 498.e1-498.e9.	1.2	5
9	A phase I trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2022, 40, e14015-e14015.	1.6	5
10	A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2076-TPS2076.	1.6	0
11	Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 1048-1057.	7.0	129
12	What is New in Neuro-oncology?. <i>Neurologic Clinics</i> , 2021, 39, 163-179.	1.8	3
13	The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. <i>Neuro-Oncology Advances</i> , 2021, 3, v03035.	0.7	3
14	Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. <i>Nature Communications</i> , 2021, 12, 352.	12.8	77
15	Spiritual well-being and its association with health-related quality of life in primary brain tumor patients. <i>Neuro-Oncology Practice</i> , 2021, 8, 299-309.	1.6	5
16	Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 631618.	2.8	0
17	A broad perspective on evaluating bias in the neuro-oncology workplace. <i>Neuro-Oncology</i> , 2021, 23, 498-499.	1.2	3
18	When tumefactive demyelination is truly a tumor: case report of a radiographic misdiagnosis. <i>CNS Oncology</i> , 2021, 10, CNS69.	3.0	2

#	ARTICLE	IF	CITATIONS
19	Palliative Care Use for Critically Ill Patients With Brain Metastases. <i>Journal of Pain and Symptom Management</i> , 2021, 62, 927-935.	1.2	2
20	Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4491-4499.	7.0	112
21	Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman. <i>CNS Oncology</i> , 2021, 10, CNS71.	3.0	4
22	Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis. <i>CNS Oncology</i> , 2021, 10, CNS77.	3.0	3
23	Multi-joint steroid-induced avascular necrosis in a malignant brain tumor patient. <i>CNS Oncology</i> , 2021, 10, CNS78.	3.0	1
24	QOLP-10. A LONGITUDINAL OBSERVATIONAL STUDY OF EXERCISE BEHAVIOR IN GLIOBLASTOMA PATIENTS TREATED WITH TUMOR-TREATING FIELDS. <i>Neuro-Oncology</i> , 2021, 23, vi184-vi185.	1.2	0
25	Targeting BRAF-mutant glioma: reflections on the ROAR trial. <i>Lancet Oncology</i> , The, 2021, , .	10.7	3
26	INNV-20. RADIOGRAPHIC RESPONSE AND SEIZURE CONTROL IN IDH1 MUTANT GLIOMA PATIENTS USING IVOSIDENIB. <i>Neuro-Oncology</i> , 2021, 23, vi109-vi109.	1.2	3
27	Preservation of neurocognitive function in the treatment of brain metastases. <i>Neuro-Oncology Advances</i> , 2021, 3, v96-v107.	0.7	6
28	CTIM-10. REPRODUCIBILITY OF CLINICAL TRIALS USING CMV-TARGETED DENDRITIC CELL VACCINES IN PATIENTS WITH GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi51-vi51.	1.2	2
29	Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. <i>Supportive Care in Cancer</i> , 2020, 28, 2229-2238.	2.2	9
30	Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study. <i>Neuro-Oncology</i> , 2020, 22, 694-704.	1.2	23
31	Health care resource utilization and treatment of leptomeningeal carcinomatosis in the United States. <i>Neuro-Oncology Practice</i> , 2020, 7, 636-645.	1.6	0
32	Ibrutinib in primary central nervous system diffuse large B-cell lymphoma. <i>CNS Oncology</i> , 2020, 9, CNS51.	3.0	9
33	Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series. <i>Journal of Neuro-Oncology</i> , 2020, 147, 477-483.	2.9	4
34	RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events. <i>Neuro-Oncology Practice</i> , 2020, 7, 369-375.	1.6	2
35	Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. <i>Neuro-Oncology</i> , 2020, 22, 1822-1830.	1.2	23
36	CTIM-21. PEPTIDE VACCINE DIRECTED TO CMV pp65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL. <i>Neuro-Oncology</i> , 2020, 22, ii37-ii37.	1.2	4

#	ARTICLE	IF	CITATIONS
37	Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population.. Journal of Clinical Oncology, 2020, 38, 2504-2504.	1.6	4
38	INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.. Journal of Clinical Oncology, 2020, 38, TPS2574-TPS2574.	1.6	12
39	Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).. Journal of Clinical Oncology, 2020, 38, 2566-2566.	1.6	4
40	BMX-HGG: Phase II trial of newly diagnosed high-grade glioma treated with concurrent radiation therapy, temozolomide, and BMX-001.. Journal of Clinical Oncology, 2020, 38, TPS2577-TPS2577.	1.6	0
41	Utilizing a Palliative Care Screening Tool in Patients With Glioblastoma. Journal of the Advanced Practitioner in Oncology, 2020, 11, 684-692.	0.4	1
42	RTID-05. INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF VORASIDENIB (AG-881) VS PLACEBO IN PATIENTS WITH RESIDUAL/RECURRENT GRADE II GLIOMA WITH AN ISOCITRATE DEHYDROGENASE 1/2 (IDH1/2) MUTATION. Neuro-Oncology, 2020, 22, ii194-ii194.	1.2	2
43	NCOG-38. CLINICAL CHARACTERISTICS OF LOW GRADE GLIOMA PATIENTS WITH NON-CANONICAL IDH1 AND IDH2 MUTATIONS. Neuro-Oncology, 2020, 22, ii137-ii137.	1.2	0
44	QOLP-20. A FEASIBILITY STUDY UTILIZING MINDFULNESS MEDITATION DURING CONCOMITANT CHEMORADIATION IN MALIGNANT GLIOMA PATIENTS: HEALTH-REPORTED QUALITY OF LIFE (HRQOL) RESULTS. Neuro-Oncology, 2020, 22, ii179-ii179.	1.2	0
45	NCOG-23. PATTERNS OF DISTRESS IN OLDER PATIENTS WITH GLIOBLASTOMA: A FOLLOW-UP TO A SINGLE INSTITUTION CROSS-SECTIONAL STUDY OF DISTRESS IN PRIMARY BRAIN TUMOR PATIENTS. Neuro-Oncology, 2020, 22, ii134-ii134.	1.2	0
46	QOLP-24. ENGAGING PATIENTS AND CAREGIVERS TO IMPROVE THE IMPORTANCE AND QUALITY OF SUPPORTIVE CARE RESEARCH IN NEURO-ONCOLOGY. Neuro-Oncology, 2020, 22, ii180-ii180.	1.2	0
47	NCOG-44. NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN A PHASE II STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii138-ii139.	1.2	0
48	EPID-07. ACCESS TO GLIOBLASTOMA CLINICAL TRIALS FOR RURAL PATIENTS IN THE UNITED STATES FROM 2010-2020. Neuro-Oncology, 2020, 22, ii79-ii79.	1.2	0
49	QOLP-05. OLANZAPINE FOR REFRACTORY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN MALIGNANT GLIOMA PATIENTS. Neuro-Oncology, 2020, 22, ii175-ii175.	1.2	0
50	CTIM-32. PHASE II AND BIOMARKER STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA PATIENTS. Neuro-Oncology, 2020, 22, ii40-ii40.	1.2	0
51	CTIM-23. A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG). Neuro-Oncology, 2020, 22, ii38-ii38.	1.2	3
52	COVID-31. THE STATE OF NEURO-ONCOLOGY DURING THE COVID-19 PANDEMIC: A WORLDWIDE ASSESSMENT. Neuro-Oncology, 2020, 22, ii27-ii27.	1.2	0
53	Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population. Complementary Therapies in Clinical Practice, 2019, 36, 43-48.	1.7	5
54	TRLS-10. MITIGATING NEUROCOGNITIVE DEFICITS FROM WHOLE-BRAIN RADIOTHERAPY IN PATIENTS WITH NUMEROUS BRAIN METASTASES VIA A NOVEL SUPEROXIDE DISMUTASE MIMETIC: RATIONALE & DESIGN OF A CLINICAL TRIAL. Neuro-Oncology Advances, 2019, 1, i10-i10.	0.7	0

#	ARTICLE	IF	CITATIONS
55	Second primary cancers in long-term survivors of glioblastoma. <i>Neuro-Oncology Practice</i> , 2019, 6, 386-391.	1.6	12
56	Neurooncology Research in Nigeria: Great Untapped Potential. <i>World Neurosurgery</i> , 2019, 124, 381-385.	1.3	7
57	ACTR-66. A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS. <i>Neuro-Oncology</i> , 2019, 21, vi28-vi29.	1.2	17
58	ATIM-24. DOSE FINDING AND DOSE EXPANSION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). <i>Neuro-Oncology</i> , 2019, 21, vi6-vi6.	1.2	1
59	ATIM-27. TUMOR MUTATIONAL BURDEN PREDICTS RESPONSE TO ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF TRANSCRIPTIONAL AND IMMUNOLOGICAL CORRELATES. <i>Neuro-Oncology</i> , 2019, 21, vi7-vi7.	1.2	5
60	ATIM-31. SAFETY OF TUMOR-SPECIFIC PEPTIDE VACCINE TARGETING ISOCITRATE DEHYDROGENASE 1 MUTATION IN RECURRENT RESECTABLE LOW GRADE GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2019, 21, vi8-vi8.	1.2	0
61	QOLP-18. A TIME-BASED MODEL OF EARLY PALLIATIVE CARE INTERVENTION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA, A SINGLE INSTITUTION FEASIBILITY STUDY. <i>Neuro-Oncology</i> , 2019, 21, vi201-vi201.	1.2	2
62	QOLP-29. MINDFULNESS MEDITATION PRACTICE IN MALIGNANT GLIOMA PATIENTS THROUGHOUT CONCOMITANT RADIATION AND TEMOZOLOMIDE: A FEASIBILITY STUDY. <i>Neuro-Oncology</i> , 2019, 21, vi204-vi204.	1.2	1
63	QOLP-31. ASSESSING THE IMPACT OF GLIOBLASTOMA ON WORK PRODUCTIVITY IN PATIENTS AND THEIR CAREGIVERS. <i>Neuro-Oncology</i> , 2019, 21, vi204-vi204.	1.2	0
64	QOLP-20. IMPACT OF GLIOBLASTOMA ON PATIENT-REPORTED SYMPTOM BURDEN AND PHYSICAL ACTIVITY ASSESSED BY CONVENTIONAL INSTRUMENTS AND A NOVEL DEVICE-BASED TECHNOLOGY. <i>Neuro-Oncology</i> , 2019, 21, vi201-vi202.	1.2	2
65	Performance of a nomogram for IDH-wild-type glioblastoma patient survival in an elderly cohort. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz036.	0.7	4
66	HOUT-27. HEALTHCARE RESOURCE UTILIZATION OF LEPTOMENINGEAL CARCINOMATOSIS IN THE UNITED STATES. <i>Neuro-Oncology</i> , 2019, 21, vi117-vi118.	1.2	0
67	HOUT-21. CHARACTERISTICS OF SHORT-TERM SURVIVAL IN PATIENTS WITH GLIOBLASTOMA: A RETROSPECTIVE ANALYSIS. <i>Neuro-Oncology</i> , 2019, 21, vi116-vi116.	1.2	0
68	INNV-19. SURVEYING BIAS IN NEURO-ONCOLOGY AND SOCIETY FOR NEURO ONCOLOGY (SNO) MEMBERS: GENDER AND BEYOND. <i>Neuro-Oncology</i> , 2019, 21, vi134-vi134.	1.2	1
69	INNV-18. THE AVAILABILITY AND ROLE OF CLINICAL PHARMACISTS IN THE AMBULATORY NEURO-ONCOLOGY SETTING: AN INTERNATIONAL SURVEY. <i>Neuro-Oncology</i> , 2019, 21, vi134-vi134.	1.2	0
70	QOLP-09. IMPACT OF GLIOBLASTOMA (GBM) PATIENTS' CLINICAL AND TREATMENT CHARACTERISTICS ON CAREGIVER BURDEN AND QUALITY OF LIFE (QOL). <i>Neuro-Oncology</i> , 2019, 21, vi199-vi199.	1.2	0
71	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2060-2060.	1.6	2
72	Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma. <i>Journal of Clinical Oncology</i> , 2019, 37, e13526-e13526.	1.6	8

#	ARTICLE	IF	CITATIONS
73	Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma. <i>Oncologist</i> , 2018, 23, 889-e98.	3.7	26
74	Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. <i>Oncologist</i> , 2018, 23, 157-e21.	3.7	44
75	Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2018, 137, 349-356.	2.9	49
76	QOLP-17. REVIEW AND META-ANALYSIS OF NAUSEA AND VOMITING TRIALS FOR MALIGNANT GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi218-vi218.	1.2	1
77	RBTT-03. A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PERIOPERATIVE STUDY OF AG-120 (IVOSIDENIB) AND AG-881 IN PATIENTS WITH RECURRENT, NONENHANCING, IDH1-MUTANT, LOW-GRADE GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi234-vi234.	1.2	4
78	ACTR-31. PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION. <i>Neuro-Oncology</i> , 2018, 20, vi18-vi18.	1.2	12
79	HOUT-19. TREATMENT PATTERNS, OUTCOMES, AND PROGNOSTIC INDICATORS IN ELDERLY PATIENTS WITH GLIOBLASTOMA: A RETROSPECTIVE SINGLE INSTITUTION ANALYSIS. <i>Neuro-Oncology</i> , 2018, 20, vi117-vi117.	1.2	0
80	RARE-16. CLINICAL AND HISTOPATHOLOGICAL CHARACTERISTICS OF YOUNG ADULTS WITH GLIOBLASTOMA AT DIAGNOSIS. <i>Neuro-Oncology</i> , 2018, 20, vi239-vi239.	1.2	0
81	ACTR-28. PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi17-vi17.	1.2	1
82	QOLP-13. PSYCHOSOCIAL DISTRESS IN PATIENTS WITH RECURRENT MENINGIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi217-vi217.	1.2	0
83	ATIM-36. DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). <i>Neuro-Oncology</i> , 2018, 20, vi9-vi9.	1.2	2
84	ATIM-27. INTRATUMORAL ADMINISTRATION OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIP0) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF MUTATIONAL RESPONSE CORRELATES. <i>Neuro-Oncology</i> , 2018, 20, vi7-vi7.	1.2	0
85	RBTT-02. ENHANCING VACCINE RESPONSES WITH DOSE-INTENSIFIED TEMOZOLOMIDE IN GLIOBLASTOMA: INITIATION OF THE I-ATTAC TRIAL. <i>Neuro-Oncology</i> , 2018, 20, vi234-vi234.	1.2	0
86	Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade Glioma. <i>Seminars in Oncology Nursing</i> , 2018, 34, 472-485.	1.5	7
87	INNV-21. AN OVERVIEW OF NIGERIAN NEURO-ONCOLOGY SCHOLARLY OUTPUT. <i>Neuro-Oncology</i> , 2018, 20, vi142-vi142.	1.2	0
88	Adjunctive perampanel for glioma-associated epilepsy. <i>Epilepsy & Behavior Case Reports</i> , 2018, 10, 114-117.	1.5	26
89	Recurrent Glioblastoma Treated with Recombinant Poliovirus. <i>New England Journal of Medicine</i> , 2018, 379, 150-161.	27.0	570
90	A Diffuse Leptomeningeal Glioneuronal Tumor Without Diffuse Leptomeningeal Involvement: Detailed Molecular and Clinical Characterization. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 751-756.	1.7	25

#	ARTICLE	IF	CITATIONS
91	Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma.. Journal of Clinical Oncology, 2018, 36, 2002-2002.	1.6	25
92	Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients.. Journal of Clinical Oncology, 2018, 36, 2006-2006.	1.6	49
93	Impact of glioblastoma (GBM)-related cognitive dysfunction (CD) on caregiver burden: Preliminary results from multi-site study in the U.S.. Journal of Clinical Oncology, 2018, 36, 16-16.	1.6	1
94	Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2037-2037.	1.6	0
95	A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab. Therapeutics and Clinical Risk Management, 2017, Volume 13, 33-40.	2.0	6
96	Algorithmic three-dimensional analysis of tumor shape in MRI improves prognosis of survival in glioblastoma: a multi-institutional study. Journal of Neuro-Oncology, 2017, 132, 55-62.	2.9	26
97	Radiogenomic analysis of lower grade glioma: a pilot multi-institutional study shows an association between quantitative image features and tumor genomics. , 2017, , .		3
98	Radiogenomics of lower-grade glioma: algorithmically-assessed tumor shape is associated with tumor genomic subtypes and patient outcomes in a multi-institutional study with The Cancer Genome Atlas data. Journal of Neuro-Oncology, 2017, 133, 27-35.	2.9	74
99	Management of glioblastoma in elderly patients. Journal of the Neurological Sciences, 2017, 380, 250-255.	0.6	40
100	A cross sectional analysis from a single institutionâ€™s experience of psychosocial distress and health-related quality of life in the primary brain tumor population. Journal of Neuro-Oncology, 2017, 134, 363-369.	2.9	18
101	Single-Agent Carboplatin for a Rare Case of Pilocytic Astrocytoma of the Spinal Cord in an Adult with Neurofibromatosis Type 1. Case Reports in Oncology, 2017, 9, 568-573.	0.7	3
102	Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma.. Journal of Clinical Oncology, 2017, 35, e13532-e13532.	1.6	2
103	Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).. Journal of Clinical Oncology, 2017, 35, e13533-e13533.	1.6	0
104	Reductions in exercise behavior and tumor progression in newly diagnosed glioblastoma (GBM) patients.. Journal of Clinical Oncology, 2017, 35, e21636-e21636.	1.6	0
105	Treatment through progression with ofranogene obadenovec (VB-111), an anti-cancer viral therapy, significantly attenuates tumor growth in recurrent GBM: Individual phase 2 patient data.. Journal of Clinical Oncology, 2017, 35, 2055-2055.	1.6	0
106	Insomnia and its associations in patients with recurrent glial neoplasms. SpringerPlus, 2016, 5, 823.	1.2	25
107	Postictal Magnetic Resonance Imaging Changes Masquerading as Brain Tumor Progression: A Case Series. Case Reports in Oncology, 2016, 9, 358-362.	0.7	6
108	Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience. CNS Oncology, 2016, 5, 137-144.	3.0	18

#	ARTICLE	IF	CITATIONS
109	Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by Mn(III) <i>n</i> -butoxyethylpyridylporphyrin-based redox modifier. <i>Environmental and Molecular Mutagenesis</i> , 2016, 57, 372-381.	2.2	17
110	Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients. <i>CNS Oncology</i> , 2016, 5, 241-249.	3.0	40
111	Radiogenomics of glioblastoma: a pilot multi-institutional study to investigate a relationship between tumor shape features and tumor molecular subtype. <i>Proceedings of SPIE</i> , 2016, , .	0.8	4
112	Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ). <i>Supportive Care in Cancer</i> , 2016, 24, 4365-4375.	2.2	9
113	Antiangiogenic virotherapy: VB-111 targeting glioma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 1099-1103.	0.8	1
114	Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 2010-2010.	1.6	38
115	Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2061-2061.	1.6	17
116	Ofranogene obadenovec (VB-111), an anti-cancer gene therapy in combination with bevacizumab to improve overall survival compared to bevacizumab monotherapy in patients with rGBM: A phase 2 historically controlled trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2074-2074.	1.6	3
117	Phase I trial of combination of antitumor immunotherapy targeted against <i>cytomegalovirus</i> (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).. <i>Journal of Clinical Oncology</i> , 2016, 34, e13518-e13518.	1.6	6
118	Baseline cognitive function to predict survival in patients with glioblastoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10125-10125.	1.6	1
119	ATCT-01PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RILOTUMUMAB AND BEVACIZUMAB (BEV) IN SUBJECTS WITH RECURRENT MALIGNANT GLIOMA (MG). <i>Neuro-Oncology</i> , 2015, 17, v1.1-v1.	1.2	1
120	QOL-21DIET AND HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN THE PRIMARY BRAIN TUMOR POPULATION. <i>Neuro-Oncology</i> , 2015, 17, v192.3-v192.	1.2	0
121	Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma. <i>Oncologist</i> , 2015, 20, 727-728.	3.7	32
122	Radioprotection of the Brain White Matter by Mn(III) <i>n</i> -Butoxyethylpyridylporphyrin-Based Superoxide Dismutase Mimic MnTnBuOE-2-PyP5+. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 70-79.	4.1	60
123	Supratentorial Tanycytic Ependymoma in an Adult Male: Case Report and Review of Literature. <i>Case Reports in Oncology</i> , 2015, 8, 159-163.	0.7	2
124	Use of bevacizumab in recurrent glioblastoma. <i>CNS Oncology</i> , 2015, 4, 157-169.	3.0	32
125	Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2034-2034.	1.6	4
126	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2068-2068.	1.6	9

#	ARTICLE	IF	CITATIONS
127	Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.. Journal of Clinical Oncology, 2015, 33, 2067-2067.	1.6	0
128	Phase 1 clinical trial of carboxyamidotriazole orotate (CTO) in combination with lomustine (CCNU) for adult patients with recurrent malignant glioma (MG).. Journal of Clinical Oncology, 2015, 33, e13004-e13004.	1.6	0
129	Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients.. Journal of Clinical Oncology, 2015, 33, 9553-9553.	1.6	1
130	Secondary cancers in long-term survivors of primary glioblastoma.. Journal of Clinical Oncology, 2015, 33, e20616-e20616.	1.6	0
131	Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).. Journal of Clinical Oncology, 2015, 33, e13030-e13030.	1.6	0
132	Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients. Journal of Neuro-Oncology, 2014, 120, 499-506.	2.9	50
133	QL-21 * SPIRITUAL WELL-BEING AND ITS ASSOCIATION WITH HEALTH-RELATED QUALITY OF LIFE IN PRIMARY BRAIN TUMOR PATIENTS. Neuro-Oncology, 2014, 16, v182-v183.	1.2	0
134	Tumor progression and transformation of low-grade glial tumors associated with pregnancy. Journal of Neuro-Oncology, 2014, 116, 113-117.	2.9	33
135	Phase I study of the intratumoral administration of an oncolytic polio/rhinovirus recombinant (PVSRIPO) in recurrent glioblastoma (GBM).. Journal of Clinical Oncology, 2014, 32, TPS2106-TPS2106.	1.6	1
136	Single-institution retrospective review of newly diagnosed glioblastoma (GBM) patients (pts) treated on bevacizumab (BEV) in clinical practice.. Journal of Clinical Oncology, 2014, 32, 2082-2082.	1.6	0
137	Long-term survivorship in adult primary glioblastoma: Clinical and neurological outcomes of a large, single-center study.. Journal of Clinical Oncology, 2014, 32, 9519-9519.	1.6	1
138	Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM).. Journal of Clinical Oncology, 2014, 32, 3069-3069.	1.6	0
139	Acquired stuttering due to recurrent anaplastic astrocytoma. BMJ Case Reports, 2013, 2013, bcr2013009562-bcr2013009562.	0.5	7
140	Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT.. Journal of Clinical Oncology, 2013, 31, e13015-e13015.	1.6	1
141	Phase I/II dose-escalation study of VB-111, an antiangiogenic gene therapy, in patients with recurrent glioblastoma multiforme.. Journal of Clinical Oncology, 2013, 31, TPS2102-TPS2102.	1.6	2
142	Analysis of high-dose methotrexate with rituximab versus other treatment regimens for primary central nervous system (CNS) lymphoma.. Journal of Clinical Oncology, 2013, 31, 2090-2090.	1.6	0
143	Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.. Journal of Clinical Oncology, 2013, 31, 2094-2094.	1.6	4
144	Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer, 2012, 118, 1302-1312.	4.1	132

#	ARTICLE	IF	CITATIONS
145	Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2012, 107, 155-164.	2.9	123
146	Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2027-2027.	1.6	1
147	Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG). <i>Journal of Clinical Oncology</i> , 2012, 30, 2074-2074.	1.6	2
148	Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure. <i>Journal of Clinical Oncology</i> , 2012, 30, 2095-2095.	1.6	0
149	Safety and efficacy of the addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma multiforme. <i>Journal of Clinical Oncology</i> , 2012, 30, 2094-2094.	1.6	15
150	The addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM). <i>Journal of Clinical Oncology</i> , 2012, 30, 2090-2090.	1.6	1
151	Transformation of Juvenile Pilocytic Astrocytoma to Anaplastic Pilocytic Astrocytoma in Patients With Neurofibromatosis Type I. <i>Journal of Pediatric Hematology/Oncology</i> , 2011, 33, e198-e201.	0.6	11
152	Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy. <i>Journal of Neuro-Oncology</i> , 2011, 101, 155-159.	2.9	24
153	Exercise Behavior, Functional Capacity, and Survival in Adults With Malignant Recurrent Glioma. <i>Journal of Clinical Oncology</i> , 2011, 29, 2918-2923.	1.6	107
154	Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report. <i>Case Reports in Oncology</i> , 2010, 3, 93-97.	0.7	25